{"url_path":"/sec/mira/8-k/2026-06-17/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Other Exhibits.**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-17","source_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-028992-index.html","accession_number":"0001493152-26-028992","cik":"0001904286","ticker":"MIRA","issuer_name":"MIRA PHARMACEUTICALS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1904286/0001493152-26-028992-index.html","primary_entity_key":"0001904286","primary_entity_name":"MIRA PHARMACEUTICALS, INC."},"word_count":98,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Other Exhibits.**\n\n \n\n(d)\nExhibits.\n\n \n\nExhibit\nNo.\n \nDescription\n\n99.1\n \n[Press Release of MIRA Pharmaceuticals, Inc., dated June 17, 2026](ex99-1.htm)\n\n99.2\n \n[FDA Acknowledgment of Receipt — Phase 2a Clinical Trial Protocol Submission, Protocol Mira-002](ex99-2.htm)\n\n104\n \nCover\nPage Interactive Data File (embedded within the Inline XBRL document)\n\n \n\n \n\n \n\n** **\n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\n \n**MIRA\nPHARMACEUTICALS, INC.**\n\n \n \n                                \n\nDated:\nJune 17, 2026\nBy:\n*/s/\nErez Aminov*\n\n \nName: \nErez\nAminov\n\n \nTitle:\nChief\nExecutive Officer"}